 REDWOOD CITY, Calif. BOSTON--BUSINESS WIRE--Adicet Bio, Inc. Nasdaq: ACET, a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor CAR T cell therapies for cancer, today announced that company management will participate in three upcoming investor conferences in August. Details of the events are as follows: BTIG Biotech Conference, August 8-9, 2022 Chen Schor, President CEO, will participate in a fireside ch 